#BEGIN_DRUGCARD DB00578

# AHFS_Codes:
Not Available

# ATC_Codes:
J01CA03

# Absorption:
Rapidly absorbed from the small intestine following oral administration. Oral bioavailability is 30 to 40%.

# Biotransformation:
Minimal.

# Brand_Mixtures:
Not Available

# Brand_Names:
Geopen
Pyopen

# CAS_Registry_Number:
4697-36-3

# ChEBI_ID:
3393

# Chemical_Formula:
C17H18N2O6S

# Chemical_IUPAC_Name:
(2S,5R,6R)-6-(2-carboxy-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function. [PubChem]

# Dosage_Forms:
Tablet, film coated	Oral

# Drug_Category:
Anti-Bacterial Agents
Penicillins

# Drug_Interactions:
Demeclocycline	Possible antagonism of action
Doxycycline	Possible antagonism of action
Mestranol	This anti-infectious agent could decreases the effect of the oral contraceptive
Methacycline	Possible antagonism of action
Methotrexate	The penicillin increases the effect and toxicity of methotrexate
Minocycline	Possible antagonism of action
Oxytetracycline	Possible antagonism of action
Rolitetracycline	Possible antagonism of action
Tetracycline	Possible antagonism of action

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
1.13

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
451 mg/L

# Food_Interactions:
Take on an empty stomach.

# GenBank_ID:
Not Available

# Generic_Name:
Carbenicillin

# HET_ID:
Not Available

# Half_Life:
1 hour

# InChI_Identifier:
InChI=1S/C17H18N2O6S/c1-17(2)11(16(24)25)19-13(21)10(14(19)26-17)18-12(20)9(15(22)23)8-6-4-3-5-7-8/h3-7,9-11,14H,1-2H3,(H,18,20)(H,22,23)(H,24,25)/t9?,10-,11+,14-/m1/s1

# InChI_Key:
InChIKey=FPPNZSSZRUTDAP-UWFZAAFLSA-N

# Indication:
For the treatment of acute and chronic infections of the upper and lower urinary tract and in asymptomatic bacteriuria due to susceptible strains of bacteria.

# KEGG_Compound_ID:
C06869

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
578

# Mechanism_Of_Action:
Free carbenicillin is the predominant pharmacologically active fraction of the salt. Carbenicillin exerts its antibacterial activity by interference with final cell wall synthesis of susceptible bacteria. Penicillins acylate the penicillin-sensitive transpeptidase C-terminal domain by opening the lactam ring. This inactivation of the enzyme prevents the formation of a cross-link of two linear peptidoglycan strands, inhibiting the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that carbenicillin interferes with an autolysin inhibitor.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
378.4

# Molecular_Weight_Mono:
378.088557008

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA448788

# Pharmacology:
Carbenicillin is a semisynthetic penicillin. Though carbenicillin provides substantial <i>in vitro</i> activity against a variety of both gram-positive and gram-negative microorganisms, the most important aspect of its profile is in its antipseudomonal and antiproteal activity. Because of the high urine levels obtained following administration, carbenicillin has demonstrated clinical efficacy in urinary infections due to susceptible strains of: <i>Escherichia coli</i>, <i>Proteus mirabilis</i>, <i>Proteus vulgaris</i>, <i>Morganella morganii</i>, <i>Pseudomonas</i> species, <i>Providencia rettgeri</i>, <i>Enterobacter</i> species, and <i>Enterococci</i> (<i>S. faecalis</i>).

# Predicted_LogP_Hydrophobicity:
1.13

# Predicted_LogS:
-3

# Predicted_Water_Solubility:
3.90e-01 g/l

# Primary_Accession_No:
DB00578

# Protein_Binding:
30 to 60%

# PubChem_Compound_ID:
20824

# PubChem_Substance_ID:
46505653

# RxList_Link:
http://www.rxlist.com/cgi/generic3/geocillin.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00846

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C(C(O)=O)C1=CC=CC=C1)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Carbenicilina [INN-Spanish]
Carbenicillina [DCIT]
Carbenicilline [INN-French]
Carbenicillinum [INN-Latin]
Carboxybenzylpenicillin
Carboxybenzylpenicillin acid
alpha-Carboxybenzylpencillin

# Synthesis_Reference:
Not Available

# Toxicity:
Carbenicillin blood levels achievable are very low, and toxic reactions as a function of overdosage should not occur systematically. The oral LD<sub>50</sub> in mice is 3,600 mg/kg, in rats 2,000 mg/kg, and in dogs is in excess of 500 mg/kg. The lethal human dose is not known. Symptoms of overdose include diarrhea, nausea, stomach upset, and vomiting.

# Update_Date:
2013-02-08 16:19:28 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Carbenicillin

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
PLA2G4A

# Phase_1_Metabolizing_Enzyme_1_ID:
723

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytosolic phospholipase A2

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytosolic phospholipase A2
MSFIDPYQHIIVEHQYSHKFTVVVLRATKVTKGAFGDMLDTPDPYVELFISTTPDSRKRT
RHFNNDINPVWNETFEFILDPNQENVLEITLMDANYVMDETLGTATFTVSSMKVGEKKEV
PFIFNQVTEMVLEMSLEVCSCPDLRFSMALCDQEKTFRQQRKEHIRESMKKLLGPKNSEG
LHSARDVPVVAILGSGGGFRAMVGFSGVMKALYESGILDCATYVAGLSGSTWYMSTLYSH
PDFPEKGPEEINEELMKNVSHNPLLLLTPQKVKRYVESLWKKKSSGQPVTFTDIFGMLIG
ETLIHNRMNTTLSSLKEKVNTAQCPLPLFTCLHVKPDVSELMFADWVEFSPYEIGMAKYG
TFMAPDLFGSKFFMGTVVKKYEENPLHFLMGVWGSAFSILFNRVLGVSGSQSRGSTMEEE
LENITTKHIVSNDSSDSDDESHEPKGTENEDAGSDYQSDNQASWIHRMIMALVSDSALFN
TREGRAGKVHNFMLGLNLNTSYPLSPLSDFATQDSFDDDELDAAVADPDEFERIYEPLDV
KSKKIHVVDSGLTFNLPYPLILRPQRGVDLIISFDFSARPSDSSPPFKELLLAEKWAKMN
KLPFPKIDPYVFDREGLKECYVFKPKNPDMEKDCPTIIHFVLANINFRKYKAPGVPRETE
EEKEIADFDIFDDPESPFSTFNFQYPNQAFKRLHDLMHFNTLNNIDVIKEAMVESIEYRR
QNPSRCSVSLSNVEARRFFNKEFLSKPKA

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P47712

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
20974151	Sainsbury S, Bird L, Rao V, Shepherd SM, Stuart DI, Hunter WN, Owens RJ, Ren J: Crystal structures of penicillin-binding protein 3 from Pseudomonas aeruginosa: Comparison of native and antibiotic-bound forms. J Mol Biol. 2010 Oct 22.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Not Available

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
Not Available

# Drug_Target_1_Gene_Sequence:
Not Available

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
Not Available

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
7177

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
Not Available

# Drug_Target_1_Name:
Pencillin Binding Protein 3, P. aeruginosa

# Drug_Target_1_Number_of_Residues:
0

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
Not Available

# Drug_Target_1_Protein_Sequence:
Not Available

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
Not Available

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Not Available

# Drug_Target_1_SwissProt_Name:
Not Available

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
Not Available

# Drug_Target_1_Transmembrane_Regions:
Not Available

#END_DRUGCARD DB00578
